Takatsuki, Japan

Tomoe Kamei


Average Co-Inventor Count = 4.7

ph-index = 2

Forward Citations = 39(Granted Patents)


Location History:

  • Osaka, JP (2003)
  • Takatsuki, JP (2001 - 2006)

Company Filing History:


Years Active: 2001-2006

Loading Chart...
8 patents (USPTO):Explore Patents

Title: Tomoe Kamei: Innovator in Pharmaceutical Chemistry

Introduction

Tomoe Kamei is a notable inventor based in Takatsuki, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target serotonin receptors. With a total of 8 patents to his name, Kamei's work has implications for treating various circulatory diseases.

Latest Patents

Kamei's latest patents include innovative compounds such as pyrrolothiazine and pyrrolothiazepine. These compounds exhibit serotonin-2 receptor antagonistic and alpha-1-blocking actions. The specific pyrrolesulfonamide derivative he developed has a unique structure that allows for strong therapeutic effects with low toxicity and fewer side effects. This makes it particularly useful for treating ischemic heart diseases, cerebrovascular disturbances, and peripheral circulatory issues.

Career Highlights

Throughout his career, Kamei has worked with prominent companies in the pharmaceutical industry, including Suntory Limited and Daiichi Suntory Pharma Co., Ltd. His expertise in drug development has positioned him as a key figure in advancing therapeutic options for patients.

Collaborations

Kamei has collaborated with notable colleagues such as Akira Mizuno and Makoto Shibata. These partnerships have fostered innovation and contributed to the successful development of his patented compounds.

Conclusion

Tomoe Kamei's contributions to pharmaceutical chemistry highlight his role as an influential inventor. His work continues to pave the way for advancements in treatments for circulatory diseases, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…